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Abstract
Purpose To optimize a C-arm computed tomography
(CT) protocol for radioembolization (RE), specifically for
extrahepatic shunting and parenchymal enhancement.
Materials and Methods A prospective development study
was performed per IDEAL recommendations. A literature-
based protocol was applied in patients with unresectable
and chemorefractory liver malignancies undergoing an
angiography before radioembolization. Contrast and scan
settings were adjusted stepwise and repeatedly reviewed in
a consensus meeting. Afterwards, two independent raters
analyzed all scans. A third rater evaluated the SPECT/CT
scans as a reference standard for extrahepatic shunting and
lack of target segment perfusion.
Results Fifty scans were obtained in 29 procedures. The
first protocol, using a 6 s delay and 10 s scan, showed
insufficient parenchymal enhancement. In the second pro-
tocol, the delay was determined by timing parenchymal
enhancement on DSA power injection (median 8 s, range
4–10 s): enhancement improved, but breathing artifacts
increased (from 0 to 27 %). Since the third protocol with a
5 s scan decremented subjective image quality, the second
protocol was deemed optimal. Median CNR (range) was
1.7 (0.6–3.2), 2.2 (-1.4–4.0), and 2.1 (-0.3–3.0) for pro-
tocol 1, 2, and 3 (p = 0.80). Delineation of perfused seg-
ments was possible in 57, 73, and 44 % of scans
(p = 0.13). In all C-arm CTs combined, the negative
predictive value was 95 % for extrahepatic shunting and
83 % for lack of target segment perfusion.
Conclusion An optimized C-arm CT protocol was
developed that can be used to detect extrahepatic shunts
and non-perfusion of target segments during RE.
Keywords C-arm CT  Cone beam CT 
Radioembolization  IDEAL  Protocol optimization
Introduction
C-arm cone beam computed tomography (CT) can be used
to acquire, reconstruct, and display high-resolution 3D
images of selective contrast-enhanced vessels and the
surrounding soft-tissue. Hence, it can provide valuable
information on vascular anatomy and tissue perfusion
during intra-arterial liver-directed treatments, such as trans-
arterial chemoembolization (TACE) or radioembolization.
However, the specific purpose for C-arm CT imaging may
differ from treatment to treatment.
During TACE, C-arm CT is performed to identify the
lesion of interest and all tumor-feeding arteries, to plan and
navigate to the intended injection position, and to confirm
adequacy of the injection position by evaluating contrast
enhancement of the targeted tumor [1–4]. In contrast,
during radioembolization, C-arm CT is used to map the
hepatic arterial anatomy, to identify extrahepatic branches,
and to rule out extrahepatic shunting or non-perfusion of a
target volume [5, 6]. The latter allows for additional
measures to be taken before the administration of tech-
netium-99 m-labeled macro-albumin aggregates (99mTc-
MAA) and acquisition of single-photon emission computed
tomography (SPECT). Since extrahepatic deposition of
99mTc-MAA is reported in 10–20 % of patients after a
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workup solely based on digital subtraction angiography
(DSA) [7, 8], C-arm CT could significantly reduce the
number of angiography procedures that need to be
repeated.
As these imaging purposes differ, they require other
acquisition protocols, with appropriate timing of the con-
trast injection and scan delay. Thus far, an optimal acqui-
sition protocol that enables the use of a single-run C-arm
CT for radioembolization purposes has yet to be estab-
lished. Furthermore, even though C-arm CT is increasingly
performed, evidence for its added diagnostic value in
radioembolization is still scarce. Thus, a clear need exists
for the development and validation of a C-arm CT protocol
for radioembolization.
The Innovation, Development, Exploration, Assessment,
Long-term Study (IDEAL) recommendations describe how
to perform a study with these aims [9]. These guidelines
were initially formulated to provide a framework for a
responsible stepwise evaluation of surgical innovations, but
they also apply to complex interventions in the field of
interventional radiology [10]. The first stage (‘Stage 1:
Idea’) of evaluation is to perform a proof of concept study
for a novel idea in a few selected patients. The next stage
(‘Stage 2a: Development’) is the early development stage,
in which prospective development studies should be per-
formed in 10–100 patients to determine which technique
has the best chance for procedural success, treatment effi-
cacy, and safety. It is a crucial stage that differs the most
from the pharmacological evaluations in the phase I–IV
trial paradigm. ‘‘IDEAL supports prospective rather than
retrospective studies at this stage, with sequential reporting
of all cases and outcomes without omissions, and with clear
explanations of when and how technique, design, or indi-
cations were changed’’ [11]. If these studies provide con-
vincing evidence for safety and short-term benefits, the
innovation enters the exploration stage (‘Stage 2b: Explo-
ration’). The goal of this stage is to learn as much as
possible about the safety and benefits of the procedure as
patients and operators vary. Large, prospective, observa-
tional studies with registry data collection are particularly
suited for this purpose. The last two stages (‘Stage 3:
Assessment’ and ‘Stage 4: Long term study’) of evaluation
are quite similar to pharmacological phase III and IV trials.
Large (multicenter) randomized controlled trials are
indispensable to assess comparative effectiveness of
the innovation versus the current standard of care, and
surveillance studies, preferably integrated in national
patient registries, are needed to assess long-term safety and
effectiveness outcomes [12].
The use of C-arm CT during radioembolization is still in
‘Stage 2A: Development.’ Accordingly, the purpose of this
study was to develop a C-arm CT protocol optimized for
the detection of extrahepatic shunting and non-perfusion of
a target volume during radioembolization.
Materials and Methods
Study Design
A prospective development study was performed in
accordance with phase 2A of the IDEAL recommenda-
tions, consisting of two parts: Part (1) prospective, step-
wise, optimization of our C-arm CT protocol in clinical
practice, and Part (2) blinded analysis of C-arm CT image
quality and its diagnostic value.
C-arm CTs were already part of clinical practice during
radioembolization procedures in our center, but the added
value was limited to vascular mapping only, and the scan
protocol was dependent on the operator. With the aim to
reduce the number of repeat procedures for extrahepatic
shunting or missed target segments, the protocol was
optimized and then modified based on clinical experience.
The medical ethics committee of the University Medical
Center Utrecht waived the need for informed consent for
reviewing imaging data in patients undergoing radioem-
bolization in our center.
Reporting was done in agreement with the Strengthen-
ing the Reporting of Observational Studies in Epidemiol-
ogy (STROBE) and the research reporting standards for
radioembolization [13, 14].
Study Population
All patients undergoing a pretreatment angiography during
workup for radioembolization were eligible for C-arm
CT acquisition, and thus for participation in our study.
These patients had unresectable and chemorefractory liver
malignancies (either primary tumors or metastasized),
liver-dominant disease, a life expectancy exceeding three
months, WHO performance status[2, hepatic tumor load
B70 % of the liver volume, and unimpaired hepatic, renal,
and hematological functions. Mirroring clinical practice,
operators could refrain from acquiring a C-arm CT, if they
deemed the additional contrast load too high in patients
with previous allergic reactions, or when C-arm CT was
considered of no added value in a particular patient (for
example, in an ultra-selective injection position during
segmental treatment of a single tumor).
Technique, Equipment, and Scan Settings
The workup for radioembolization was performed follow-
ing current standards of practice [15]. At baseline, patients
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received a 18F-FDG-PET scan combined with a multipha-
sic liver CT to (1) rule out contra-indications such as celiac
axis stenosis, main portal vein thrombosis, or dominant
extrahepatic disease, (2) localize the liver tumors, (3)
assess the individual hepatic arterial anatomy, and (4)
determine a patient-based treatment strategy [16]. During
the pretreatment angiography, the hepatic arterial vascu-
lature was selectively catheterized by femoral approach
with a standard 5F guiding catheter (Celiac, Cobra or
Simmons shape), 2.7F Progreat microcatheter (Terumo,
Leuven, Belgium), and a 0.014-inch Transend guide wire
(Boston Scientific, Natick, MA, USA). The celiac axis,
common/proper hepatic artery, and left/middle/right hep-
atic arteries were selectively catheterized in all patients.
The left gastric artery and superior mesenteric artery were
only selectively catheterized when an aberrant hepatic
artery was demonstrated on the pretreatment CT. Power
injection DSA was used to search for potential sources of
extrahepatic shunting. Coil embolization of extrahepatic
branches was restricted to cases in which it was absolutely
necessary to avoid extrahepatic shunting. Eventually, the
microcatheter was positioned in the target vessel(s), and a
C-arm CT acquisition was performed. A non-sequential,
whole-liver approach with two or more selective injection
positions was used in patients with bilobar disease. A lobar/
segmental approach was used in patients with tumors
confined to a single lobe or segment.
An Allura Xper FD20 (Philips, Best, The Netherlands)
system, equipped with the XperCT and EmboGuide
options, was used for the C-arm CT acquisitions. The
abdomen fast high dose (HD) or abdomen fast low-dose
(LD) settings were used. Depending on the setting, 312
(LD) or 624 (HD) images were acquired in a scan time of 5
(LD) or 10 (HD) seconds during a 240 rotation (Table 1).
Delay was defined as the time period between start of
the contrast injection and start of the scan. Acquisition time
was defined as the sum of the delay and scan time. Contrast
agent (iodixanol 270 mg/ml, Visipaque 270; GE Health-
care) was diluted 1:1 with 0.9 % NaCl solution to reduce
beam hardening artifacts and to limit the contrast burden.
The injection of contrast agent was continued during the
entire acquisition time in order to obtain images with
contrast enhancement of the vascular tree and liver par-
enchyma. Injection rates were similar to those typically
used in the common, proper, left, and right hepatic artery
during power injector DSA.
The C-arm CT images were reviewed in the angio suite,
and additional measures were taken if deemed necessary.
Consequently, a total of 150 MBq 99mTc-MAA were
administered, and SPECT/CT images were acquired on a
Symbia T16 scanner (Siemens Healthcare, Erlangen,
Germany).
Part 1: Protocol Optimization in Clinical Practice
Based on a literature review by two authors (AvdH, JP), a
first protocol was defined. Starting from October 2013, all
C-arm CTs were performed using this protocol.
After a predefined number of 5 patients, image quality
and usefulness were subjectively assessed, and the need to
alter one of the acquisition parameters was discussed in a
consensus meeting between three investigators (AvdH, JP,
EJV). This process was repeated until a protocol was found
with sufficient image quality, allowing for both visualiza-
tion of the arterial tree and detection of missed target
segments and extrahepatic shunting. After optimization,
further C-arm CTs were performed with that particular
protocol, to expand the study population.
Part 2: Retrospective Analysis of Image Quality
and Diagnostic Value
Consequently, a retrospective analysis of image quality and
diagnostic value was performed. For this purpose, scans
were anonymized and randomized. For evaluation, Osirix
(v.5.8 32-bit for MacOS X) was used. Reconstructions
were made in the axial plane, using a window level of 60
HU and window width of 350 HU, with maximum inten-
sity projections of 5 mm. Two raters (AvdH, JP) inde-
pendently determined the vessel from which contrast was
injected, the ability to discriminate between the perfused
and non-perfused liver territory (categorized as ‘‘Yes’’,
‘‘Partially’’, and ‘‘No’’), the presence of breathing artifacts,
whether the field of view (FOV) contained the whole liver,
the presence of extrahepatic shunting and the culprit vessel,
and the presence of a non-perfused liver segment and if so,
which one(s). Extrahepatic shunting was defined as a
sharply defined area of contrast enhancement in the gastric
wall, pancreas, duodenum, or bowel (excluding the gall-
bladder wall as an extrahepatic location). Discrepancies
between the two raters were resolved during a subsequent
consensus meeting.
Table 1 Differences between
scan settings
Parameters Abdomen fast high dose Abdomen fast low dose
Rotation time 10.4 s 5.2 s
Number of images 624 312
Maximum rotation speed 20 per second 41 per second
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For quantitative analyses, both raters drew six volumes
of interest (VOIs), three in the perfused liver lobe and three
in the non-perfused. Each VOI was placed in an area of the
liver that was representative for the enhancement of the
liver lobe, with a size between 1 and 10 cm2 to allow for
proper estimation of the signal standard deviation (SD).
Mean Hounsfield units (HU) and SD of the signal in the
VOI were noted. The three VOIs were combined by
averaging the three mean HU values. The SDs were com-
bined using Eq. 1.
SDCombined ¼
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ




For calculation of the signal to noise ratio (SNR), the
following formula was used [17]:
SNR ¼ MeanðHUÞ
SD ðHU) : ð2Þ
The contrast to noise ratio (CNR) was calculated to
demonstrate differences between the perfused and non-
perfused liver territories relative to the background noise in
the liver parenchyma, by using the following formula [18]:




The average of both raters was used as CNR to test for
differences between the three protocols. All image quality
analyses were performed on a scan basis.
SPECT/CT images were retrospectively reviewed by a
nuclear medicine physician (BdK) with experience in the
field of radioembolization (indication, patient management,
administration, and evaluation). He was blinded for the
outcome of the two raters evaluating the C-arm CT. The
rater was asked to evaluate the presence of extrahepatic
deposition in the gastric wall, pancreas, duodenum or
bowel, and total lack of 99mTc-MAA activity in one of the
liver segments. This served as reference test to evaluate the
diagnostic accuracy of C-arm CT. Negative predictive
values (NPV) were determined for extrahepatic shunting
and non-perfusion of a target volume. The diagnostic value
analyses were performed on a procedure basis. For a pro-
cedure to be evaluated, C-arm CTs had to be acquired in all
catheter positions in which 99mTc-MAA was injected.
Statistics
Differences in CNR between the three protocols were
tested using an ANOVA. A Fisher–Freeman–Halton exact
test was used to compare the subjective score for dis-
criminating ability between protocols. A p value\ 0.05
was considered statistically significant. All statistical




A flowchart of this study is displayed in Fig. 1. From
October 2013 until February 2014, we performed 37 pre-
treatment angiographies in 32 patients in our institute.
During 31 angiography procedures, a total of 62 C-arm
CTs were obtained in 28 different patients. The majority of
C-arm CTs were performed during the first pretreatment
angiography (n = 26), four were performed during repeat
procedures, and 1 during the second pretreatment angiog-
raphy for the treatment of a different liver lobe (n = 1).
Fig. 1 Detailed flowchart of the selection process showing the
number of scans, procedures, and patients. Asterisk indicates that the
number of unique patients is 26. Two patients were scanned with
more than one protocol
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Twelve C-arm CTs had to be excluded for the following
reasons: the FOV was incorrect (n = 4 scans), the injection
parameters were unknown (n = 4), the catheter was dis-
placed during contrast injection (n = 1), the wrong
acquisition settings were used (n = 1), the scan was made
after treatment (n = 1), and no contrast was injected
(n = 1). For two procedures, these scans were the only
C-arm CTs available; these two patients were excluded,
leaving a total of 50 scans acquired during 29 procedures in
26 patients for analysis.
The patients included in this study had a median age of
64 years (range 45–80 years), and 16/26 (62 %) were
male. They were treated for primary or metastatic liver
tumors, with the following primary tumor types: colorectal
cancer (n = 10, 37 %), hepatocellular carcinoma (n = 6,
23 %), cholangiocarcinoma (n = 2, 8 %), breast cancer
(n = 2, 8 %), and others (n = 6, 24 %). Median tumor
burden was 14 % (range 0–66 %), WHO performance
score was 0 in 18 patients (69 %), 1 in 3 patients (12 %), 2
in 1 patient (4 %), and not reported in 4 patients (15 %).
Child Pugh score was A5 in the majority of patients
(n = 24, 92 %), A6 in one patient (4 %), and not reported
in another patient (4 %).
Part 1: Protocol Optimization in Clinical Practice
For the first protocol, a fixed delay of 6 s was chosen based
on a literature review, combined with the high-dose scan
setting of 10 s. After the first protocol was applied during 5
procedures (8 C-arm CTs, 5 unique patients), the degree of
parenchymal contrast enhancement was deemed insuffi-
cient. To improve the parenchymal enhancement, it was
decided to use a variable delay. This delay was determined
by assessing the time to parenchymal enhancement on
power injection DSA, using an identical injection rate and
catheter position (Fig. 2). This method adjusts for differ-
ences between liver lobes and between patients.
For the second protocol, a variable delay (median 8 s,
range 3–10 s) and 10-s high-dose scan setting were used.
This protocol was used during 10 procedures (17 scans in
9 patients). Parenchymal contrast enhancement had
improved substantially in comparison with the first proto-
col. However, the relatively long scan time was associated
with breathing artifacts (from 0 to 27 %).
In the third protocol, used during 7 procedures (12 scans
in 7 patients), a 5 s low-dose scan setting was applied to
reduce breathing artifacts, in combination with a variable
delay (median 8 s, range 4–10 s). It did show considerably
less breathing artifacts, and parenchymal contrast
enhancement was acceptable. Still, this protocol was not
favored over the second protocol, because the low-dose
scan settings had led to deterioration of the overall image
quality.
The second protocol was subsequently used in another 7
procedures (13 scans in 7 patients), bringing it to a total use
in 17 procedures (30 scans in 16 patients).
Part 2: Retrospective Analysis of Image Quality
and Diagnostic Value
For image quality analysis, eight of these scans were
obtained with protocol 1, 30 scans with protocol 2, and 12
scans with protocol 3.
The results of the image quality analysis are summarized
in Table 2. The median CNR (range) for discrimination
between the perfused and non-perfused liver territories was
1.7 (0.6–3.2) for protocol 1, 2.2 (-1.4 to 4.0) for protocol
2, and 2.1 (-0.3–3.0) for protocol 3 (p = 0.80). The
Fig. 2 Example of how the C-arm CT scan delay was determined on
power injection DSA in the right hepatic artery. A Start of the DSA
run. Only vascular contrast enhancement is visible. B Midway the
DSA run. Parenchymal contrast enhancement of the right liver lobe
(white arrows indicate the border of the right liver lobe) is starting to
show. C At the end of the DSA run, maximal parenchymal contrast
enhancement is reached. The time between the first and last run is
used as delay for the C-arm CT scan
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subjective score for discriminating ability was Yes—Par-
tially—No, in 57 %—29 %—14 % of evaluable scans for
protocol 1, 73 %—27 %—0 % of scans for protocol 2, and
44 %—33 %—22 % of scans for protocol 3 (p = 0.13).
Nine scans (29 protocol 1, 49 protocol 2, 39 protocol 3)
could not be evaluated for the discriminating ability due to
the absence of a non-perfused territory. Breathing artifacts
were reported in none of the scans for protocol 1, 8/30
scans (27 %) for protocol 2, and 1/12 (8 %) scans for
protocol 3.
For diagnostic accuracy analysis, 25/29 (86 %) proce-
dures were evaluable: a C-arm CT was not obtained in all
injection positions in 2 procedures, a dissection hampered
SPECT/CT acquisition in 1 procedure, and C-arm CTs
were not assessable due to breathing artifacts in 1
procedure.
In 21/25 procedures (84 %, Table 3), the retrospective
C-arm CT analysis revealed no extrahepatic shunting. In
one of the 21 procedures, SPECT/CT analysis demon-
strated extrahepatic deposition of 99mTc-MAA. This


















1 6 s 10 Fast HD 8 1.7 (0.6–3.2) 4 (57 %) 2 (29 %) 1 (14 %) 1
2 Variablea 10 Fast HD 30 2.2 (-1.4–4.0) 19 (73 %) 7 (27 %) 0 (0 %) 4
3 Variablea 5 Fast LD 12 2.1 (-0.3–3.0) 4 (44 %) 3 (33 %) 2 (22 %) 3
The protocol settings, number of scans per protocol, objective (CNR), and subjective ability to discriminate between perfused and non-perfused
liver territories are displayed in Table 1
CNR contrast to noise ratio, HD high dose, LD low dose
a Estimated by contrast-enhanced DSA series where time between infusion and liver parenchyma enhancement is used as the delay time for
C-arm CT
Table 3 Diagnostic outcomes—gastrointestinal shunting
Gastrointestinal shunting 99mTc-MAA SPECT/CT
Present Absent Total
C-arm CT Present 3 1 4
Absent 1 20 21
Total 4 21 25
Negative predictive value 95.2 %
Two by two table displaying the presence and absence of gastroin-
testinal shunting on C-arm CT (experimental test) and 99mTc-MAA
SPECT/CT (reference standard). The numbers represent the number
of procedures
Fig. 3 A Extrahepatic deposition of 99mTc-MAA activity in the
region of the coil embolized right gastric artery on a fusion SPECT/
CT image (white arrow). B On C-arm CT imaging, no extrahepatic
shunting was noted, due to the extensive coil-related beam hardening
artifacts (white arrow)
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extrahepatic deposition occurred near the implanted coils in
the right gastric artery and could not be detected on theC-arm
CT (Fig. 3). The negative predictive value for extrahepatic
shunting was 95 %. It should be noted that during 3 proce-
dures (14 %), extrahepatic shunting had already been
observed on C-arm CT in clinical practice. In two of these
patients, an extrahepatic branch (pancreatic/duodenal
branch from the RHA, collateral between cystic artery and
the gastroduodenal artery) was successfully coil embolized,
before the administration of 99mTc-MAA. In the other
patient, the catheter was positioned distal to the extrahepatic
branch (gastric branch originating from the LHA). Success
was confirmed by a repeated C-arm CT scan without extra-
hepatic shunting (see Fig. 4 for an example).
In our retrospective evaluation, C-arm CT showed
extrahepatic shunting in 4/25 procedures (16 %), located in
the duodenal region (n = 3) or stomach wall (n = 1). The
SPECT/CT analysis confirmed extrahepatic deposition in 3
of these procedures (Fig. 5).
Out of the 25 procedures that were assessable for the
perfusion of target liver territories, 7 (28 %) showed one or
more unperfused target segments in the C-arm CT analysis
(Table 4). Five out of those 7 procedures also showed a
lack of perfusion on 99mTc-MAA (Fig. 6). In the two
remaining patients, segments I and IV showed no contrast
enhancement on C-arm CT, but 99mTc-MAA activity was
visible on SPECT/CT. Both patients had markedly hyper-
vascular tumors with a heterogeneous contrast and 99mTc-
MAA activity distribution. Furthermore, in 3/18 procedures
with adequate perfusion on C-arm CT, lack of 99mTc-MAA
activity was found on SPECT/CT (in segments I-IVb,
segment VII, and segments I-V ? VIII) in the retrospec-
tive analysis. The negative predictive value for non-per-
fusion was 83 %.
Fig. 4 A DSA from the LHA. B C-arm CT performed from the LHA
shows extrahepatic shunting in the gastric wall (white arrow). The
small extrahepatic branch indicated by the white arrow in (A) was the
culprit vessel. C The catheter was positioned more distal in the LHA.
D C-arm CT performed from the new injection position did not show
extrahepatic shunting anymore
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Discussion
In this study, an acquisition protocol for C-arm CT imaging
has been developed that meets specific needs during
radioembolization procedures.
We have shown that a continuous infusion of contrast
agent, a variable scan delay based on the time to
parenchymal enhancement on DSA, and a 10 s high-dose
scan setting resulted in images that contain both contrast
enhancement of the arterial tree and liver parenchyma
show gastrointestinal shunting, and provide sufficient
contrast between perfused and non-perfused liver territo-
ries, all in a single C-arm CT run. It is expected that
optimization of these acquisition parameters increases the
detection rate of angiographic failures, providing an
opportunity to take additional measures and prevent
unnecessary repeat procedures.
In our series, the NPV for extrahepatic shunting and
non-perfusion were 95 and 83 % respectively, which is in
line with the results of two previous studies. In 2009, Louie
et al. performed a study in 42 patients who underwent
radioembolization for primary and metastatic liver tumors.
In a total of 22/42 patients (52 %), extrahepatic shunting or
incomplete tumor perfusion on C-arm CT affected the
treatment plan. In the majority (14/22 patients), these
findings were not detected on DSA. Extrahepatic shunting
was demonstrated on C-arm CT in 8 patients (19 %), and
only in 1 on SPECT/CT. According to the authors, this
incongruence can be explained by the limited spatial res-
olution of SPECT/CT. Interestingly, 1 patient with extra-
hepatic shunting on C-arm CT developed a gastric ulcer
upon follow-up, as a complication of extrahepatic yttrium-
90 microsphere deposition [5].
Later, Heusner et al. assessed the accuracy of C-arm CT
for the detection of extrahepatic shunting before RE in 30
patients with primary and metastatic liver tumors in a
similar type of study. Using 99mTc-MAA SPECT/CT as
reference standard, they found a negative predictive value
of 96 %, and C-arm CT detected extrahepatic shunting that
was not visible on DSA in 10 % of their patients [6].
Other studies reported that arterial and parenchymal
enhancement images can also be acquired in two separate
C-arm CT scans using two different delay times, or by
means of a customized dual-phase C-arm CT setting that
allows back-to-back acquisitions of two scans with a single
contrast injection [3, 19]. In our opinion, it is easier to
continue the contrast infusion during the entire acquisition
time (delay ? scan time). This also provides the benefit
Fig. 5 Comparison of C-arm CT and SPECT/CT in a patient with
extrahepatic shunting. A C-arm CT shows extrahepatic shunting in
the duodenal region (black arrow), caused by a collateral branch from
the cystic artery. B Corresponding extrahepatic 99mTc-MAA activity
in the duodenal region on SPECT/CT (white arrow)
Table 4 Diagnostic outcomes—non-perfused target volumes
Non-perfused target volume 99mTc-MAA SPECT/CT
Present Absent Total
C-arm CT Present 5 2 7
Absent 3 15 18
Total 8 17 25
Negative predictive value 83.3 %
Two by two table displaying the presence and absence of non-per-
fused target volumes on C-arm CT (experimental test) and 99mTc-
MAA SPECT/CT (reference standard). The numbers represent the
number of procedures
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that potential extrahepatic shunting and the culprit vessel
can be identified in the same image.
Now the technical aspects have been refined and the
feasibility of C-arm CT as a diagnostic tool is demon-
strated; there is a window of opportunity to rigorously test
its diagnostic value in accordance with ‘Stage 2B: Explo-
ration’ and ‘Stage 3: Assessment’ of the IDEAL recom-
mendations. C-arm CT is not likely to replace the infusion
of 99mTc-MAA, for the latter is also used for the evaluation
of lung shunting and dosimetric evaluation. Nevertheless,
C-arm CT may come to play an important role in evalu-
ating the pretreatment angiographies, since it allows for
timely intervention to prevent repeat angiographies. Fur-
thermore, C-arm CT is, as an adjunct to a multiphasic
pretreatment CT, indispensable in the development of a
single-day treatment algorithm for radioembolization [20].
The current study suffers from a relatively small sample
size, as is common in the developmental phase of a new
technique. To prevent bias, all consecutive cases were
described and their reasons for inclusion/exclusion were
mentioned. Also, there was no predefined plan for the
modifications to the scan protocol, it was adjusted by the
needs identified by the consensus meeting. Furthermore,
there is no clear end point for an optimal scan protocol, so
other studies may improve on this proposal. For our diag-
nostic accuracy evaluation, it was not possible to assess the
false positive rate for C-arm CT, since additional measures
were taken when extrahepatic shunting was detected during
the preparatory angiography. Besides, the operator was
allowed to refrain from using C-arm CT. In theory, this
may introduce selection bias. However, in most cases, there
was a reason to refrain from C-arm CT (e.g., contrast
allergy). Finally, 99mTc-MAA SPECT/CT was used as a
reference standard, but this modality also has limitations.
Its limited spatial resolution and room for registration
errors between SPECT and CT volumes can make the
detection of extrahepatic deposition a challenging task.
Furthermore, 99mTc-MAA SPECT/CT is an imperfect
predictor for the posttreatment yttrium-90 microsphere
distribution. Therefore, future investigations should deter-
mine the definite role of C-arm CT and 99mTc-MAA
SPECT/CT in the workup for radioembolization.
In conclusion, we have developed an optimized C-arm
CT protocol that can be used to detect extrahepatic shunts
and non-perfusion of target segments during RE. Its use is
currently in the developmental phase, and needs to be
further evaluated in the near future.
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